High BMI May Cut Overall Survival in HER2 & #43; Metastatic Breast Cancer
WEDNESDAY, Feb. 12, 2020 -- For patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC) treated with pertuzumab and/or trastuzumab emtansine (T-DM1), a body mass index (BMI) of ≥30 kg/m² is... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 12, 2020 Category: Pharmaceuticals Source Type: news

Trazimera (Trastuzumab-qyyp) for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 10, 2020 Category: Drugs & Pharmacology Source Type: news

NCI-MATCH: T-DM1 shows promising activity in salivary gland cancer
(ECOG-ACRIN Cancer Research Group) A discovery from NCI-MATCH, the largest precision medicine cancer trial, relates to patients with salivary gland cancer treated with ado-trastuzumab emtansine (T-DM1), a drug already FDA-approved for certain types of breast cancer. Two of the three NCI-MATCH patients with this rare disease saw their tumors shrink by at least 30% with T-DM1 treatment and the benefit lasted two years for one patient and nine months for the other. Another recent trial reported similar benefits. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 7, 2020 Category: International Medicine & Public Health Source Type: news

Watchdog rejects use of genetic disorders drug in the NHS
NICE will not approve volanesorsen on the NHS Related items fromOnMedica NICE recommends Herceptin for gastric cancer H. pylori eradication linked to reduced risk of gastric cancer Use of DPP-4 inhibitors associated with increased risk of IBD Aspirin could also treat cancer, research suggests Antivirals cut liver cancer risk after hepatitis C (Source: OnMedica Latest News)
Source: OnMedica Latest News - January 6, 2020 Category: UK Health Source Type: news

Trastuzumab with Adjuvant Chemotherapy Reduces Risk of Relapse in HER2+ Breast Cancer
An analysis of the results of the phase III PANTHER trial showed that a combination of tailored dose-dense adjuvant chemotherapy and trastuzumab decreased the relative risk of relapse for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - January 3, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Enhertu (Fam-trastuzumab Deruxtecan-nxki for Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 31, 2019 Category: Drugs & Pharmacology Source Type: news

Enhertu Approved for Unresectable, Metastatic HER2 & #43; Breast Cancer
MONDAY, Dec. 23, 2019 -- Enhertu (fam-trastuzumab deruxtecan-nxki) has received accelerated approval for treatment of unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer, the U.S. Food and Drug... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 23, 2019 Category: General Medicine Source Type: news

Obesity is a risk factor for cardiotoxicity in chemotherapy-treated patients with breast cancer
(PLOS) A recent study showed that being overweight or obese was a risk factor for cardiotoxicity in chemotherapy-treated patients with breast cancer, but it did not take into account related cardiac risk factors or other classic risk factors of cardiotoxicity produced by anthracycline and trastuzumab. In a study published Dec. 23 in the open-access journal PLOS Medicine, Elis é Kabor é of Centre Georges-Fran ç ois Leclerc and Charles Guenancia of University Hospital, Dijon, France, and colleagues address this gap in knowledge. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 23, 2019 Category: Cancer & Oncology Source Type: news

FDA OKs New Antibody Drug Conjugate for HER2+ Breast Cancer FDA OKs New Antibody Drug Conjugate for HER2+ Breast Cancer
Trastuzumab deruxtecan is for the treatment of unresectable or metastatic HER2-positive breast cancer that has received two or more prior anti-HER2-based regimens in the metastatic setting.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 21, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer
The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (ENHERTU ®, Daiichi Sankyo) for patients with unresectable or metastatic HER2-positive breast cancer. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 20, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
Today, the U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. (Source: World Pharma News)
Source: World Pharma News - December 20, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Trastuzumab Deruxtecan for HER2-Positive Breast Cancer
The FDA granted accelerated approval to trastuzumab deruxtecan for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 20, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2 Based Regimens
20 December 2019 -- AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved Enhertu® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 20, 2019 Category: Drugs & Pharmacology Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
             Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, ...
Source: Roche Media News - December 19, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Basel, 19 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Kadcyla ® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy.“Optimal treatment is vital for every patient with early-stage breast cancer, a setting where cures are possible,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product De...
Source: Roche Investor Update - December 19, 2019 Category: Pharmaceuticals Source Type: news

Top UCLA news stories of 2019
UCLA began observing its 100th birthday this year and delivered new  advances in research, health care, the arts, community service and teaching. These are some of the top stories from UCLA Newsroom in 2019 — those which made news and engaged the community of Bruins and beyond.UCLA Newsroom will resume publishing on Jan. 2, 2020. For more, be sure toperuse the archives and to followUCLA Newsroom on Twitter. UCLA turns 100UCLA ArchiveUCLA from overhead in the 1930s.Founders of UCLA would marvel at their creationIn just 100 years, UCLA has grown into a respected center of learning, research and health ca...
Source: UCLA Newsroom: Health Sciences - December 19, 2019 Category: Universities & Medical Training Source Type: news

Scientists make 'exciting' advancement in certain breast cancer drugs
Two new drug treatments for HER2-positive breast cancer were tested in separate studies. One study involves the drug Tucatinib, and the other involves an antibody-drug called trastuzumab deruxtecan. (Source: CNN.com - Health)
Source: CNN.com - Health - December 18, 2019 Category: Consumer Health News Source Type: news

Failed ATEMPT: T-DM1 No Safer in Early HER2+ Breast Cancer Failed ATEMPT: T-DM1 No Safer in Early HER2+ Breast Cancer
Trastuzumab emtansine showed no disease-free survival or safety advantage over paclitaxel + trastuzumab in the adjuvant setting for patients with stage 1 HER2-positive breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche today announced new data from the phase III FeDeriCa study which showed the investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) and comparable efficacy and safety to standard IV infusions of Perjeta plus Hercep tin and chemotherapy in eligible people with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - December 12, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche today announced new data from the phase III FeDeriCa study which showed the investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) and comparable efficacy and safety to standard IV infusions of Perjeta plus Hercep tin and chemotherapy in eligible people with HER2-positive early breast cancer (eBC). (Source: Roche Investor Update)
Source: Roche Investor Update - December 12, 2019 Category: Pharmaceuticals Source Type: news

New Standard Likely for Some Metastatic HER2 Breast Cancer New Standard Likely for Some Metastatic HER2 Breast Cancer
The investigational oral therapy tucatinib, when added to standard trastuzumab and capecitabine, resulted in a"clinically meaningful" lower risk of disease progression or death compared with placeboMedscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

SABCS: Addition of Tucatinib Ups Survival in HER2 & #43; Metastatic Breast Cancer
WEDNESDAY, Dec. 11, 2019 -- Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 11, 2019 Category: Pharmaceuticals Source Type: news

Dana-Farber Study: New Drugs Show Rare Promise Against Advanced Breast Cancer
SAN ANTONIO (AP) — Doctors on Wednesday reported unusually good results from tests of two experimental drugs in women with an aggressive form of breast cancer that had spread widely and resisted many previous treatments. One drug showed particular ability to reach tumors in the brain, which are notoriously tough to treat. The other pairs a sort of homing device for cancer cells with a payload of chemotherapy that’s released when it reaches its target. “It’s a guided missile. It’s able to bring the chemotherapy directly to the cancer cell,” said the study leader, Dr. Ian Krop of the Dana-...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 11, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated CBSN Boston Breast Cancer Dana Farber Cancer Institute Source Type: news

' Compelling' Data on New Agent in Pretreated Breast Cancer'Compelling' Data on New Agent in Pretreated Breast Cancer
Trastuzumab deruxtecan generated durable responses in HER2-positive metastatic breast cancer that had progressed on trastuzumab emtansine and other therapies in a phase 2 study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 11, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

APHINITY six-year results strengthen evidence of clinical benefit with Roche ’s Perjeta-based regimen
Roche the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced data from a second interim overall survival (OS) analysis of the phase III APHINITY study, evaluating the combination of Perjeta ® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - December 11, 2019 Category: Pharmaceuticals Source Type: news

APHINITY six-year results strengthen evidence of clinical benefit with Roche ’s Perjeta-based regimen
             Basel, 11 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support Unit (IJB-CTSU) and Frontier Science Foundation (FS) today announced data from a second interim overall survival (OS) analysis of the phase III APHINITY study, evaluating the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) as an adjuvant (after surgery) treatment for patients with HER2-positive early breast cancer (eBC). This latest int...
Source: Roche Investor Update - December 11, 2019 Category: Pharmaceuticals Source Type: news

Trastuzumab deruxtecan achieved a tumour response rate of 60.9% in pivotal Phase II HER2-positive metastatic breast cancer trial
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody drug conjugate (ADC) and potential new medicine, in patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens. (Source: World Pharma News)
Source: World Pharma News - December 11, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Adding tucatinib to drug combination extends survival for advanced HER2+ breast cancer patients
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center today reported study results showing the addition of tucatinib to capecitabine (Xeloda) and trastuzumab (Herceptin) significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced HER2-positive breast cancer, with and without brain metastasis according to results of the HER2CLIMB clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2019 Category: Cancer & Oncology Source Type: news

Addition of Pertuzumab to Previous Standards Improves IDFS in HER2+ Breast Cancer
The addition of pertuzumab to the previous standard of trastuzumab plus chemotherapy as an adjuvant therapy for patients with operable HER2-positive early breast cancer continued to reduce the risk for recurrence and death during a 6-year updated analysis. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Trastuzumab Deruxtecan Shows Promise in Heavily Pretreated Patients With HER2+ BC
T-DXd demonstrated improved and durable response rates in heavily pretreated patients with advanced HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 11, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

AI-Enabled Stethoscope Brings Specialized Knowledge to the Point of Care
Recent results of a collaborative study between Eko and the Mayo Clinic demonstrating the use of Eko’s DUO digital stethoscope as a heart failure screening tool suggest that the device could help identify asymptomatic patients with low ejection fraction during routine physical examinations. “The low ejection fraction algorithm was used with a very specific protocol of four touchpoints—three on the chest and one on the fingers,” said Steve Pham, MD, vice president of clinical and research affairs at Eko, in an interview with MD+DI. â&#...
Source: MDDI - December 11, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Digital Health Source Type: news

Biocon and Mylan nab FDA approval for Herceptin biosim
Co-developed by both companies, Ogivri will be used for the treatment of breast and gastric cancer patients. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 3, 2019 Category: Pharmaceuticals Source Type: news

Biosimilar for HER2+ breast cancer: Overall response rate matches reference trastuzumab
(European Society for Medical Oncology) The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast cancer, according to a large, randomised phase III study reported at the ESMO Asia 2019 Congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 22, 2019 Category: Cancer & Oncology Source Type: news

CHMP recommends EU approval of Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. (Source: Roche Media News)
Source: Roche Media News - November 15, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kadcyla® (trastuzumab emtansine) for the adjuvant (after surgery) treatment of adult patients with HER2-positive early breast cancer (eBC) who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - November 15, 2019 Category: Pharmaceuticals Source Type: news

Treatment with anti-cancer drug T-DM1 after pertuzumab is 'good option'
(European School of Oncology) Patients with HER2-positive breast cancer, whose disease has progressed after being treated initially with pertuzumab in combination with trastuzumab and a taxane, can respond well to treatment with T-DM1 -- a drug that combines trastuzumab with an anti-cancer drug called DM1. The research is presented at the Advanced Breast Cancer Fifth International Consensus Conference (ABC5) and published simultaneously in published in Clinical Breast Cancer journal. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 14, 2019 Category: Cancer & Oncology Source Type: news

Trial Results Support Frontline Use of T-DM1 in HER2 ‐Positive Metastatic Breast Cancer
Treatment with trastuzumab emtansine demonstrated similar overall survival across 3 treatment arms of patients with HER2 ‐positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 9, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review. (Source: World Pharma News)
Source: World Pharma News - October 17, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2+ Metastatic Breast Cancer
The agency is set to make a decision on the investigational antibody drug conjugate by the first quarter of 2020. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2019 Category: Cancer & Oncology Authors: Seth Augenstein Source Type: news

NICE rejects immunotherapy drug for breast cancer
Watchdog wants manufacturer to make drug more cost-effective Related items fromOnMedica New breast cancer drug ‘unaffordable’ for NHS NICE rejects breast cancer drug for NHS funding Pledge to give all women same level of cancer care HRT users told to discuss breast cancer risk with GP Benefit of Herceptin in more breast cancer cases (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 4, 2019 Category: UK Health Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
Roche today announced the phase III FeDeriCa study met its primary endpoint. The study showed a new investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard IV infusion of Perjeta plus Herceptin and chemotherapy in peo ple with HER2-positive early breast cancer (eBC). (Source: Roche Media News)
Source: Roche Media News - September 13, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
Roche today announced the phase III FeDeriCa study met its primary endpoint. The study showed a new investigational fixed-dose combination (FDC) of Perjeta ® (pertuzumab) and Herceptin® (trastuzumab), administered by subcutaneous (SC) injection in combination with intravenous (IV) chemotherapy, demonstrated non-inferior levels of Perjeta in the blood (pharmacokinetics) compared to standard IV infusion of Perjeta plus Herceptin and chemotherapy in peo ple with HER2-positive early breast cancer (eBC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 13, 2019 Category: Pharmaceuticals Source Type: news

Lasker Awards Honor Advances in Modern Immunology
The prizes recognized the discoverers of B and T lymphocytes, pioneers in genetic engineering to fight breast cancer, and a nonprofit that helps get vaccines to the world ’s poorest children. (Source: NYT Health)
Source: NYT Health - September 10, 2019 Category: Consumer Health News Authors: Knvul Sheikh Tags: Lasker Awards Breast Cancer Vaccination and Immunization Immune System Children and Childhood your-feed-science Herceptin (Drug) Third World and Developing Countries Lymph Nodes and Lymphatic System Genetics and Heredity Thymus Gland Source Type: news

Laskers Go to Immunologists, Developers of Breast Cancer Therapy
The 2019 Lasker medical and research awards celebrate advances in scientists’ understanding of T and B cells, Herceptin antibodies for treating breast cancer, and vaccine coverage around the... (Source: The Scientist)
Source: The Scientist - September 10, 2019 Category: Science Tags: News & Opinion Source Type: news

UCLA oncologist Dennis Slamon wins 2019 Lasker Award for clinical medical research
Physician-scientist Dr. Dennis Slamon, professor and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking development of breast cancer drug Herceptin (trastuzumab), a lifesaving therapy for women with HER2-positive breast cancer. He shares the award with H. Michael Shepard, an American cancer researcher honored for work he completed at biotechnology company Genentech; and Axel Ullrich, a German cancer researcher from the Max Planck Institute of Biochemistry.The Albert and Mary Lasker Foundation honored Sl...
Source: UCLA Newsroom: Health Sciences - September 10, 2019 Category: Universities & Medical Training Source Type: news

Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs. The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - September 7, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Genentech nears trade secrets suit settlement with Taiwanese company but still targeting former employees
Biotech powerhouse Genentech Inc. is close to settling a with a Taiwanese company that allegedly stole trade secrets and planned to launch a look-alike version of one of Genentech's most popular drugs. The settlement between the South San Francisco-based U.S. unit of drug giant Roche and JHL Biotech Inc. requires the Taiwanese company to stop development of biosimilar versions of Genentech's cancer drugs Rituxan, Herceptin and Avastin — all multibillion-dollar biologics — and the cystic fibr osis… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 7, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

Pledge to give all women same level of cancer care
Best practice to be shared across cancer networks Related items fromOnMedica Exercise and psychological treatments cut cancer fatigue Cancer patients using complementary meds die sooner Data don ’t support HRT for chronic disease prevention Benefit of Herceptin in more breast cancer cases New breast cancer drug ‘unaffordable’ for NHS (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 27, 2019 Category: UK Health Source Type: news

Do Early Changes to Dosing of T-DM1 Affect Outcomes in HER2-Positive Breast Cancer?
A new analysis looked at how dose interruptions or reductions of  ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Where Does T-DM1 Fit In First-Line Treatment for HER2-Positive Breast Cancer?
A phase III trial tested trastuzumab emtansine (T-DM1) with or without pertuzumab in patients with HER2-positive metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news